Scleroderma renal crisis

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 549-554

  Hudson, Marie ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Outcomes; Pathogenesis; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

ENDOTHELIN 1;

FOLLOW UP; HUMAN; IMMUNOPATHOLOGY; INTERNATIONAL COOPERATION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RARE DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCLERODERMA; SCLERODERMA RENAL CRISIS; KIDNEY DISEASES; METABOLISM; SCLERODERMA, SYSTEMIC;

ENDOTHELIN-1; HUMANS; KIDNEY DISEASES; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84942518862     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000221     Document Type: Review

References (33)

1. Hudson M, et al. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects. Clin Exp Rheumatol 2013; 32 (6 Suppl 86): S-127-S-132.
2. Steen VD, et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76:779-786.
3. Walker UA, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754-763.
4. Hudson M, et al. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2014; 43:666-672.
5. Avouac J, et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 2014.
6. Ghrenassia E, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014; 41:99-105.
7. Lynch B, et al. Scleroderma renal crisis and pulmonary arterial hypertension are very rare in the same patient. Arthritis Rheum 2013; 65:S1106.
8. Nguyen B, et al. Association of RNA polymerase III antibodies with scleroderma renal crisis. J Rheumatol 2010; 37:1068; author reply 1069.
9. Penn H, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485-494.
10. Lynch B, et al. The prognosis of scleroderma renal crisis in RNA-polymerase III antibody-positive compared to RNA-polymerase III antibody-negative patients. Rheumatology 2014; 53 (suppl 1):i179.
11. Okano Y, Steen VD, Medsger TA Jr. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119:1005-1013.
12. Kuwana M, et al. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993; 91:1399-1404.
13. Hamaguchi Y, et al. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 2015; 67:1045-1052.
14. Patel V, et al. Anti-RNA polymerase II antibodies in a US cohort of systemic sclerosis patients: comment on the article by Hamaguchi et al. Arthritis Rheumatol 2015. [Epub ahead of print]
15. Hamaguchi Y, Kuwana M, Fujimoto M. Reply-Clinical and immunological predictors of scleroderma renal crisis for Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 2015. [Epub ahead of print]
16. Steen VD. Scleroderma renal crisis. Rheumatic diseases clinics of North America 2003; 29:315-333.
17. Nguyen B, et al. HLA-DRB1-0407 and -1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63:530-534.
18. Guerra S, et al. Defining genetic risk for scleroderma renal crisis: a genomewide analysis of anti-RNA polymerase antibody-positive systemic sclerosis. Rheumatology 2014; 54 (suppl 1):i159.
19. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654-666.
20. Batal I, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009; 40:332-340.
21. Takahashi T, et al. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement, and renal dysfunction in systemic sclerosis. Br J Dermatol 2015. [Epub ahead of print]
22. Derrett-Smith E, et al. Perturbed response to experimental renal injury in a mouse model of systemic sclerosis. Rheumatology 2014; 53 (suppl 1):176.
23. van den Hoogen F, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747-1755.
24. Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol 2003; 21 (3 Suppl 29):S29-S31.
25. Penn H, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013; 106:839-848.
26. Kobayashi H, et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999; 18:425-427.
27. Mouthon L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011; 42:95-102.
28. Dhaun N, et al. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis 2009; 54:726-731.
29. Denton C, Black C. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004; 18:271-290.
30. Teixeira L, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67:110-116.
31. Penn H, Denton CP. Diagnosis, management and prevention of scleroderma renal disease. Curr Opin Rheumatol 2008; 20:692-696.
32. Allanore Y, et al. Systemic sclerosis. Nat Rev Dis Primers 2015. [Epub ahead of print]
33. Shapiro L, et al. Development of a 'Renal Crisis Prevention Card' As an educational tool aimed at improving outcomes in high-risk patients with systemic sclerosis. Arthritis Rheumatol 2014; 66:; abstract 2716.